<DOC>
	<DOCNO>NCT00668616</DOCNO>
	<brief_summary>The purpose study determine whether treatment 4 cycle anthracycline + cyclophoshamide follow administration 4 cycle paclitaxel effective therapy 4 cy &lt; cles anthracycline adminbistration follow 4 cycle paclitaxel</brief_summary>
	<brief_title>Adjuvant Treatment Breast Cancer With 1-3 Aflicted Lymph Nodes</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>woman histologically proven breast cancer ( pT1/pT2/pT3 , pN1 , N0 ) ECOG performance status 01 start adjuvant therapy later 4 week surgery hematology : platelet least 100xGpt/l , neutrophile least 2xGpt/l normal liver function define : bilirubine till 1.5 x normal value , SGOT/SGPT till 1.25 x normal value normal kidney function define : creatine till 1.5 x normal value negative pregnancy test patient menopause effective contraception write informed consent prior radiation , chemotherapy , hormontherapy immunotherapy patient 3 afflicted lymph node afflict lymph node cantralateal side and/or afflict supraclavicular intraclavicular lymph node bilateral breast cancer second carcinoma breast inflammatory breast cancer and/or distant metastases exist clinically relevant peripheral neuropathie heart infection last 6 month therapeutically compensate heart failure cardiac arrhythmia least LOWN II patient active infection and/or control hypercalcemia pregnant breastfeed woman woman childbearing age use effictive contrazeptiva</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>breast cancer 1-3 afflict axillary lymph node</keyword>
</DOC>